JP Morgan Chase’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$76.4M Sell
358,500
-118,300
-25% -$26.2M ﹤0.01% 1122
2025
Q4
$109M Buy
476,800
+209,700
+79% +$47.8M 0.01% 905
2025
Q3
$61.8M Sell
267,100
-63,700
-19% -$13M ﹤0.01% 1278
2025
Q2
$61.4M Sell
330,800
-14,200
-4% -$2.64M ﹤0.01% 1205
2025
Q1
$72.3M Sell
345,000
-338,100
-49% -$65.7M 0.01% 1097
2024
Q4
$121M Buy
683,100
+379,500
+125% +$69.8M 0.01% 845
2024
Q3
$60M Buy
303,600
+145,400
+92% +$27.1M ﹤0.01% 1214
2024
Q2
$27.1M Buy
158,200
+67,600
+75% +$11.2M ﹤0.01% 1634
2024
Q1
$16.5M Sell
90,600
-162,800
-64% -$28.1M ﹤0.01% 2042
2023
Q4
$39.3M Buy
253,400
+217,200
+600% +$31.7M ﹤0.01% 1359
2023
Q3
$5.4M Buy
36,200
+4,700
+15% +$690K ﹤0.01% 2778
2023
Q2
$4.24M Sell
31,500
-226,500
-88% -$33.2M ﹤0.01% 2997
2023
Q1
$41.1M Sell
258,000
-33,400
-11% -$5.11M 0.01% 1196
2022
Q4
$47.1M Buy
291,400
+78,900
+37% +$12.1M 0.01% 1149
2022
Q3
$28.5M Sell
212,500
-27,100
-11% -$3.89M ﹤0.01% 1344
2022
Q2
$36.7M Sell
239,600
-131,700
-35% -$20.1M 0.01% 1205
2022
Q1
$60.2M Buy
371,300
+78,400
+27% +$11.4M 0.01% 1072
2021
Q4
$39.7M Sell
292,900
-572,000
-66% -$67.6M ﹤0.01% 1335
2021
Q3
$93.3M Buy
864,900
+476,700
+123% +$54.5M 0.01% 902
2021
Q2
$43.7M Buy
388,200
+280,500
+260% +$31.6M 0.01% 1283
2021
Q1
$11.7M Sell
107,700
-1,141,600
-91% -$122M ﹤0.01% 2223
2020
Q4
$134M Buy
1,249,300
+918,300
+277% +$88.2M 0.02% 670
2020
Q3
$28.8M Buy
331,000
+140,200
+73% +$13.2M ﹤0.01% 1267
2020
Q2
$18.7M Sell
190,800
-33,000
-15% -$2.91M ﹤0.01% 1409
2020
Q1
$17.1M Buy
223,800
+62,400
+39% +$5.32M ﹤0.01% 1359
2019
Q4
$14.3M Buy
161,400
+6,400
+4% +$531K ﹤0.01% 1829
2019
Q3
$11.7M Sell
155,000
-501,000
-76% -$34.3M ﹤0.01% 1998
2019
Q2
$45.9M Buy
656,000
+489,500
+294% +$38.5M 0.01% 1016
2019
Q1
$13.4M Sell
166,500
-174,600
-51% -$14.3M ﹤0.01% 1812
2018
Q4
$31.4M Buy
341,100
+280,900
+467% +$24.7M 0.01% 1159
2018
Q3
$5.69M Sell
60,200
-39,000
-39% -$3.7M ﹤0.01% 2639
2018
Q2
$9.19M Buy
+99,200
New +$9.69M ﹤0.01% 2211
2018
Q1
Sell
-159,100
Closed -$15.4M 5351
2017
Q4
$15.4M Buy
159,100
+25,200
+19% +$2.37M ﹤0.01% 1778
2017
Q3
$11.9M Hold
133,900
﹤0.01% 1855
2017
Q2
$9.71M Sell
133,900
-133,600
-50% -$8.98M ﹤0.01% 1995
2017
Q1
$17.4M Sell
267,500
-360,300
-57% -$22.7M ﹤0.01% 1552
2016
Q4
$39.3M Buy
627,800
+620,428
+8,416% +$37.9M 0.01% 1041
2016
Q3
$465K Sell
7,372
-3,215,825
-100% -$208M ﹤0.01% 3425
2016
Q2
$200M Buy
3,223,197
+2,878,282
+834% +$175M 0.05% 365
2016
Q1
$19.7M Sell
344,915
-94,685
-22% -$5.28M 0.01% 1349
2015
Q4
$26M Buy
439,600
+335,000
+320% +$19.3M 0.01% 1159
2015
Q3
$5.69M Buy
104,600
+74,700
+250% +$4.86M ﹤0.01% 2141
2015
Q2
$2.01M Buy
+29,900
New +$1.95M ﹤0.01% 2912
2015
Q1
Sell
-593,600
Closed -$38.8M 4039
2014
Q4
$38.8M Sell
593,600
-3,259,700
-85% -$206M 0.01% 1066
2014
Q3
$223M Buy
+3,853,300
New +$214M 0.05% 382
2013
Q4
Sell
-36,128
Closed -$1.62M 4071
2013
Q3
$1.62M Hold
36,128
﹤0.01% 2948
2013
Q2
$1.49M Buy
+36,128
New +$1.58M ﹤0.01% 3005

Other funds holding ABBV

JP Morgan Chase's ABBV Position: Q1 2026 in Review

JP Morgan Chase increased its AbbVie (ABBV) stake by 8.3% in Q1 2026, buying an estimated $965M and bringing the position to 56,741,691 shares worth $12.1B. The position accounts for 0.78% of the portfolio, ranked #19.

JP Morgan Chase first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.1B in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • JP Morgan Chase held 56,741,691 shares of AbbVie worth $12.1B as of Q1 2026.
  • JP Morgan Chase bought 4,348,368 AbbVie shares in Q1 2026, an estimated $965M.
  • AbbVie made up 0.78% of JP Morgan Chase's portfolio in Q1 2026, its #19 holding.
  • JP Morgan Chase first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's AbbVie position peaked at $13.1B in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.